AIDA International

Aida Pharmaceuticals (“Hangzhou Aida Pharmaceuticals Co.”) is an established Chinese pharmaceutical manufacturer focused on antibiotics—including the first domestically developed antibiotic “etimicin sulfate”—as well as cardiovascular drugs and genetic therapies targeting cancer such as “rh-Apo2L”. Its lead oncology candidate “doxifluridine” reached phase II trials before suspension. The company’s headquarters are located in Hangzhou with operations throughout mainland China since its founding in 1999. It trades over-the-counter under ticker “AIDA” but has limited recent financial disclosure outside Asia. Its core business remains commercializing pharmaceuticals within the Chinese market using GMP-certified facilities while maintaining ambitions toward broader international reach that have yet to materialize fully based on available data up through early 2025.[1][3][4][6]